Treatment for Opiate Addiction: Prognostic fActors of Responsiveness to Maintenance Treatment
NCT ID: NCT03729388
Last Updated: 2022-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
29 participants
OBSERVATIONAL
2019-05-28
2022-05-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Autonomous Methadone Delivery System by Nurses
NCT07085377
On-site Evaluation of Substances Consumption on Opiate Maintenance
NCT02345655
Biopsychosocial Markers of Addiction in Opioid Users: an Integrated Approach
NCT06021548
Prescription Opioid Misuse Assessment
NCT03195374
Piloting a Patient-Reported Outcome Measure for Opioid Use Disorder Recovery in a Clinical Setting
NCT05388045
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the first visit (inclusion), clinical interview, electrocardiogram, urinary and blood tests (pharmacokinetics and pharmacogenetics analysis) will be provided. Infectious disease screening and fibroscan could be also provided as the patient wishes. Inclusion visit will also correspond to initiation of OMT.
At 6 months follow-up (second visit) clinical interview, electrocardiogram, urinary and blood tests (pharmacokinetics and pharmacogenetics analysis) will be provided.
At 12 months follow-up (final visit) clinical interview, electrocardiogram and urinary test will be provided.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prognosis factor associated with good outcome.
Implementation of a systematic assessment of patient with OMT initiation. Patients included in the TOPAZE study will receive standardized clinical interviews, electrocardiograms, urinary and blood tests during a 12 months follow-up.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Initiation of treatment with OMT (methadone or buprenorphine) for an OUD moderate to severe (according to DSM 5) in Nantes Hospital addictionology department or in an addiction care and prevention centers in Nantes.
* Affiliated to social security
* Consent to participate
Exclusion Criteria
* Difficulty to understand, read or write French language
* Adult under guardianship or curatorr
* Pregnant woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CSAPA Apsyades
UNKNOWN
OPPELIA-Le triangle
UNKNOWN
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Grall Bronnec
Nantes, , France
OPPELIA-Le triangle
Nantes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC17_0377
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.